Vision Executives International Eye Care Recruitment
  • Home
  • About
  • Recruitment Services
  • Candidate Services
  • Vacancies
  • Eye Care News
  • Contact

Eye Care News

POSITIVE 3 MONTH INTERIM RESULTS FOR AGTC RETINITIS PIGMENTOSA TREATMENT

18/5/2022

0 Comments

 
Retinitis pigmentosa is an inherited eye disease which affects the retina, and impacts around 1.5 million people globally. In Vision Executives’ article on gene therapy, which was published in the The Ophthalmologist  Magazine, we explored how some companies were aiming to use gene therapy to treat retinitis pigmentosa. Applied Genetic Technologies Corporation (AGTC) are a recent addition to this selection of companies who are aiming to treat the disease with gene therapy.

AGTC have released their 3-month interim data from their phase 2 Skyline trail of AGTC-501, an AAV viral vector-based gene therapy which targets the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP). The results showed improvements in visual sensitivity in multiple patients after 3 months, the trials primary efficacy endpoint.

As with their phase 1/2 results, AGTC-501 was well tolerated with no clinically relevant safety concerns. ATGC believe this favourable safety profile is due to a strong focus on product design, extensive preclinical testing and enhanced inclusion and exclusion criteria.

“We are incredibly excited by the compelling interim results seen in the Skyline trial, including strong safety data and robust improvements in visual sensitivity with a clear difference between the two dose groups. These results add to the growing body of evidence supporting the best-in-class potential of AGTC-501 for the treatment of XLRP.” Sue Washer, President and CEO of AGTC.
AGTC-501 is an exciting development for the treatment of XLRP, a disease which currently has no FDA approved treatments.
Picture
Ref: AGTC Announces Positive 3-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa (eyewire.news)
0 Comments



Leave a Reply.

    Author

    James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.

    Archives

    December 2022
    October 2022
    September 2022
    August 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021

    Categories

    All
    Eye Care News

    RSS Feed

Picture

Location

Contact Us

Vision Executives Ltd
16 Market Place
Dewsbury
WF13 1AE
​United Kingdom

+44 (0) 1134900340
info@visionexecutives.com

Site Map

​Home
​
About
​Recruitment Services
​Candidate Services
Vacancies
Eye Care News
Contact
Vision Executives Ltd is a company registered in England & Wales. Company Number 13319387.
​Copyright © 2021 Vision Executives Ltd.
Click here to see our privacy policy.
  • Home
  • About
  • Recruitment Services
  • Candidate Services
  • Vacancies
  • Eye Care News
  • Contact